Bone resorption inhibitory composition
A composition using c-banglen, t-banglen, L-ascorbyl palmitate, crocetin, evening primrose, Indian date, and black ginger extracts addresses safety issues in osteoporosis treatments by inhibiting bone resorption and enhancing bone density, offering a safer alternative to existing drugs.
Patent Information
- Application Number
- JP2023177618
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2023-10-13
- Publication Date
- 2024-11-21
AI Technical Summary
Existing osteoporosis treatments, such as bisphosphonates and SERMs, pose safety concerns and require caution with concomitant drug use, necessitating the development of safer materials that can inhibit bone resorption and improve bone density without side effects.
A composition containing c-banglen, t-banglen, L-ascorbyl palmitate, crocetin, evening primrose extract, Indian date extract, and black ginger extract is formulated to inhibit bone resorption and enhance bone density, leveraging their natural properties without adverse effects.
The composition effectively inhibits bone resorption and improves bone density, comparable to bisphosphonates, and is suitable for various forms of administration, including food and pharmaceutical compositions, demonstrating safety and efficacy across age groups, particularly benefiting middle-aged and elderly women.
Smart Images

Figure 2024162964000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for inhibiting bone resorption. More specifically, the present invention relates to a composition for inhibiting bone resorption and a composition for improving bone density, which contain a component having bone resorption inhibitory activity. [Background technology]
[0002] Bone homeostasis is maintained by a dynamic cycle of destruction (bone resorption) and formation (bone formation), known as bone metabolism, which is carried out by osteoclasts and osteoblasts, respectively. Under normal conditions, a balance of activity between osteoclasts and osteoblasts is maintained to maintain bone shape and mass, but if this balance is disrupted and bone resorption occurs, bone mass decreases and ultimately leads to osteoporosis. Osteoporosis is a skeletal disease characterized by reduced bone strength and increased risk of fracture. Bone formation by osteoblasts is promoted by estrogen (female hormone), whereas bone resorption by osteoclasts is inhibited by estrogen. Therefore, osteoporosis is commonly seen in women whose estrogen secretion has decreased after menopause and in older men. Active calcium intake is important for the prevention and treatment of osteoporosis. However, calcium intake from food alone is insufficient to prevent bone loss, so it is desirable to actively suppress bone resorption.
[0003] Bisphosphonate preparations, selective estrogen receptor modulators (SERMs), calcitonin preparations, and the like have conventionally been used as drugs that suppress bone resorption (Non-Patent Documents 1 to 3). However, these drugs require caution in terms of side effects and the use in combination with other drugs, and safer materials for improving bone density are needed. Furthermore, recent research into bone density has revealed that various materials have the ability to inhibit bone resorption (e.g., grape seeds, quercetin, curcumin, β-cryptoxanthin, etc.).
[0004] Under these circumstances, there is a need for further research and development of materials that have the ability to inhibit bone resorption without side effects or problems such as the need to use them in combination with other drugs. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Kashida K. et al:Bone Miner. Metab. (2004) 22.462-468
[0006] [Non-Patent Document 2] Ohta H.: Clin. Calium (2004) 14.73-80
[0007] [Non-Patent Document 3] Hosoi T.: Clin. Calcium. (2007) Jul;17 (7) 1098-104. Summary of the Invention [Problem to be solved by the invention]
[0008] An object of the present invention is to provide a composition for inhibiting bone resorption and a composition for improving bone density which contain, as active ingredients, raw materials that have bone resorption inhibitory ability and are free from the risk of side effects and the like. [Means for solving the problem]
[0009] In order to search for materials that have the ability to inhibit bone resorption, the inventors screened approximately 1,500 types of materials and excluded materials that were already known to have this function.As a result, they found that c-banglene, t-banglene, L-ascorbyl palmitate, crocetin, evening primrose extract, Indian date extract and black ginger extract, which are characteristically contained in Java ginger extract, have excellent bone resorption inhibitory properties, and thus completed the present invention.
[0010] That is, the present invention provides the following composition for inhibiting bone resorption and composition for improving bone density. (1) A composition for inhibiting bone resorption comprising as an active ingredient one or more ingredients selected from the group consisting of c-banglene, t-banglene, L-ascorbyl palmitate, crocetin, Java ginger extract, evening primrose extract, Indian date extract and black ginger extract. (2) A composition for improving bone density comprising as an active ingredient one or more ingredients selected from the group consisting of c-banglene, t-banglene, L-ascorbyl palmitate, crocetin, Java ginger extract, evening primrose extract, Indian date extract and black ginger extract. [Brief description of the drawings]
[0011] [Figure 1] 1 is a graph showing the evaluation results of bone resorption inhibitory activity. [Diagram 2] 1 shows photographs showing the evaluation results of bone resorption inhibitory activity. [Diagram 3] 1 is a graph showing the results of bone density improvement evaluation. [Figure 4] 1 is a graph showing the results of bone density improvement evaluation. [Diagram 5] 1 is a graph showing the results of bone density improvement evaluation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention will now be described in detail with reference to examples. The composition for inhibiting bone resorption and the composition for improving bone density (hereinafter referred to as "composition for inhibiting bone resorption, etc.") of the present invention contain, as an active ingredient having bone resorption inhibitory ability, one or more ingredients selected from the group consisting of c-banglene or t-banglene, L-ascorbyl palmitate, crocetin, Java ginger extract, evening primrose extract, Indian date powder, and black ginger extract powder.
[0013] Of these, c-bangrene and t-bangrene are components that are characteristically contained in extracts of Java ginger (scientific name: Zingiber purpureum). c-bangrene and t-bangrene are geometric isomers of bangrene, a dimer of phenylbutadiene. Java ginger is a highly safe crop that is used as a spice and folk medicine in Southeast Asia.
[0014] L-Ascorbyl palmitate is a derivative of vitamin C and is used as a food additive as a type of antioxidant.
[0015] Crocetin is a pigment contained in the fruit of the gardenia and has long been used as a food additive. Crocetin also has excellent antioxidant properties.
[0016] Evening primrose (scientific name: Oenothera tetraptera) is a plant of the genus Oenothera in the family Onagraceae. The evening primrose extract used in the present invention is a substance obtained by concentrating polyphenols at a high concentration from the seeds of evening primrose, and is known to have strong antioxidant properties.
[0017] Indian date powder is a powder preparation derived from Indian dates (Tamarindus indica L.), which is used as food and as a folk medicine in India and other countries. It is used as a natural additive, thickener and coloring.
[0018] Black ginger extract powder is a powder of extract extracted from black ginger (scientific name: Kaempferia parviflora). Black ginger grows wild in Thailand and Laos, and is used as a folk medicine in Thailand. Black ginger extract powder contains "polymethoxyflavonoids," an active ingredient that is completely different from ginger's unique gingerol and shogaol, and various effects have been reported.
[0019] There have been no reports yet on the bone resorption inhibiting ability and bone density improving ability of these materials, and as described above, the present inventors have discovered them as a result of extensive research into approximately 1,500 types of materials. These materials may be commercially available or may be synthesized if they can be synthesized. The bone resorption inhibiting composition of the present invention may contain any one of these components or a suitable combination of two or more of them. In the present invention, the bone mineral density can be improved by the bone resorption inhibiting ability of these materials. Therefore, the present invention includes a composition for inhibiting bone resorption and a composition for improving bone mineral density.
[0020] In the present invention, the blending ratio of each component having bone resorption inhibitory ability in the bone resorption inhibiting composition etc. is not particularly limited, but is preferably 0.1 to 99 mass%, more preferably 1 to 60 mass%. The components having bone resorption inhibiting or removing ability contained in the bone resorption inhibiting composition of the present invention may be used in combination with other components, medicines, etc. having bone resorption inhibiting ability.
[0021] The bone resorption inhibiting composition of the present invention can be used as a food composition, a pharmaceutical composition, or a feed composition. The food composition is not particularly limited, and can be used as a health food, a supplement, a cosmetic food, a nutritional supplement, a functional food, a food for specified health uses, etc. In addition, the bone resorption inhibiting composition of the present invention may contain a component having efficacy or medicinal effect other than the bone resorption inhibiting component, for example, a component having bone formation promoting ability.
[0022] The bone resorption-inhibiting composition of the present invention can be used to prevent, improve, and treat osteoporosis by improving bone density. Therefore, the age and sex of the subjects of the bone resorption-inhibiting composition of the present invention are not important, and the composition is suitable for a wide range of age groups, but is particularly suitable for promoting, maintaining, and treating bone health in middle-aged and elderly women.
[0023] The form and dosage form of the bone resorption inhibiting composition of the present invention are not limited, and may be any form and dosage form, such as capsules, tablets, powders, granules, jellies, drinks, and liquids.
[0024] The bone resorption inhibiting composition of the present invention may appropriately use any raw materials such as nutritional components, excipients, and additives that are usually used in the production of food compositions, pharmaceutical compositions, and feed compositions.
[0025] Nutritional components that can be incorporated into the bone resorption inhibiting composition of the present invention include vitamins, minerals, proteins, lipids, carbohydrates, etc., and the types and amounts thereof are not limited. Examples of excipients that can be incorporated into the bone resorption inhibiting composition of the present invention include water, purified water, alcohol, glycerin, lactose, starch, dextrin, white sugar, precipitated silica, honey, etc., and the type and amount of the excipient are not limited. Additives that can be incorporated into the bone resorption inhibiting composition of the present invention include, for example, emulsifiers, coagulants, softeners, pH adjusters, enzymes, fragrances, gloss agents, bittering agents, seasonings, etc., and the types and amounts of these additives are not limited.
[0026] The daily intake or administration amount of the bone resorption inhibiting composition of the present invention is not particularly limited and varies depending on the type of active ingredient, but is preferably 0.1 mg to 3,000 mg, and more preferably 1 mg to 1,000 mg. However, the daily intake and dosage can be changed appropriately depending on the subject's symptoms, age, weight, sex, etc.
[0027] The method for producing the bone resorption inhibiting composition of the present invention is not particularly limited, and any conventional method may be used for production. EXAMPLES
[0028] The present invention will be described in detail below with reference to Test Examples and Examples. In the Test Examples and Examples, all the terms "%" simply mean "% by mass".
[0029] (Test Example 1) In this test example, a test for evaluating bone resorption activity was carried out. The materials used are as follows: (cell) Bone marrow-derived macrophages (C57BL / 6J: Charles River, prepared from mouse bone marrow)
[0030] (Test kit) A) Bone Resorption Assay Kit 48 (PG Research) ·BRA-48P (Bone resorption activity evaluation plate 48, 48WELL plate with calcium phosphate layer) · BRA-FACS (FACS for bone resorption activity evaluation, fluorescently labeled chondroitin sulfate (FACS) for labeling calcium phosphate) BRA-B (Buffer solution for evaluating bone resorption activity, used to measure fluorescence intensity) B) Luminescent cell viability assay (Cell Titer-Glo (registered trademark) Luminescent Cell Viability Assay (Promega))
[0031] (Cultures and Reagents) - Media prepared for primary culture Osteoclast culture medium (for mice) (Cosmobio Co., Ltd.) Osteoclast washing medium (Cosmo Bio) Murine M-CSF (PEPROTECH) Bisphosphonate (Tokyo Chemical Industry Co., Ltd.)
[0032] (Ingredients used) c-Banglene (c-Banglene standard (purity 96.8%): manufactured by Hosoda SHC Co., Ltd.) t-Banglene (t-Banglene standard (purity 93.0%): manufactured by Hosoda SHC Co., Ltd.) · L-Ascorbyl palmitate (DSM Nutrition Japan) Crocetin [Crovit P (manufactured by Riken Vitamin Co., Ltd.)] Evening primrose extract (Evening primrose extract-WSPS: manufactured by Oryza Oil & Fat Chemical Co., Ltd.) Indian Date Extract (Indian Date Extract Powder MF: Maruzen Pharmaceuticals) Black ginger extract (black ginger extract powder: manufactured by Koei Kogyo Co., Ltd.)
[0033] (procedure) [Day 1] (Solidification of the substrate (operated under sterile conditions)) FACS was added to BRA-48P at 0.25 mL / well, incubated at 37° C. in the dark for 80 minutes, and washed twice with phosphate buffer (PBS(-) at 0.5 mL / well). Next, 0.5 mL / well of medium was added, and the plate was protected from light and prepared for cell seeding. (Plating) The medium was aspirated, and the cells were plated (6 × 10 4 After that, the plates were incubated at 37°C and 5% CO2 for 4 days.
[0034] [Day 4] The entire medium was aspirated, and 0.5 mL of fresh medium was added. After the medium was added, each raw material was added at a final concentration of 10 μg / mL or 1 μg / mL (for raw materials that showed strong cytotoxicity at a final concentration of 10 μg / mL (c-bangrene and t-bangrene), the final concentration was set to 1 μg / mL for evaluation). As a comparative control, wells were also prepared to which bisphosphonate, a bone resorption inhibitor, was added to a final concentration of 0.05 mM.
[0035] [Day 6] -Detection and evaluation of bone resorption activity 100 μL of the culture supernatant was placed in a 96-well plate (Greiner), and 50 μL / well of BRA-B was added, followed by shaking for 2 minutes. Next, the fluorescence intensity (Ex: 485 nm, Em: 535 nm) of the culture supernatant obtained for each raw material was measured using Infinite (registered trademark) M200 (manufactured by Tecan Austria).
[0036] Cell viability assay From the 400 μL of medium remaining in the well, 200 μL was removed using a pipette so that 200 μL of medium remained in the well. Next, Cell Titer-Glo was added in an amount equal to the medium (200 μL) and the well was shaken at room temperature for 2 minutes. After incubation at room temperature for 10 minutes, 100 μL of the solution was transferred to a White 96-well plate (1 / 2 Area OptiPlate (registered trademark)-96), and luminescence was measured using Infinite (registered trademark) M200 (manufactured by Tecan Ausutria). The measurement conditions are as follows. Plate: Greiner96 Flat Bottom White Polystyrene [GRE96fw_harf area.pdfx] ·luminescence Integration time: 100ms After treatment with Cell Titer-Glo, the plate was washed with MilliQ, the cells were washed off, dried, and used for Pit observation. The measurement results of the fluorescence intensity of the culture supernatant and the cell viability assay are shown in Tables 1 and 2 and Figure 1. Photographs of the obtained plates of each material are shown in Figure 2.
[0037] The meanings of the terms in Table 1 and FIG. 1 are as follows: "RANKL" (Receptor activator of NF-κB ligand), also known as osteoclast differentiation factor (ODF), is an essential factor for osteoclast differentiation. "RANKL+" indicates the fluorescence intensity of the supernatant cultured in a medium containing RANKL (differentiation medium). "RANKL-" indicates the fluorescence intensity of the supernatant cultured in a medium not containing RANKL (non-differentiation medium). "Ave." is the average fluorescence intensity of the culture supernatant for each material (or control). "Ave.-(RANKL-)" is the value obtained by subtracting the fluorescence intensity of the supernatant cultured in a medium not containing RANKL (non-differentiation medium) from the Ave. value, and the fluorescence intensity is calculated when the background is set to 0. "RANKL+Bisphosphonate+" is the value obtained by culturing RANKL+ medium (differentiation medium) with the addition of bisphosphonate, a bone resorption inhibitor. In this system, a test was conducted to confirm that the addition of bisphosphonate, a drug used to treat osteoporosis, inhibits bone resorption. "R+Ave.- (R-)" is the average fluorescence intensity of the supernatant cultured in RANKL+ medium (differentiation medium) minus the average fluorescence intensity of the supernatant cultured in a medium that does not contain RANKL (non-differentiation medium). This value is the final control value in this test example. To evaluate how much the fluorescence intensity decreased relative to this value when each ingredient was added, the "Ave.-(RANKL-)" of each ingredient was divided by R+Ave.-(R-) to calculate " / R+Ave.-(R-)" and compared. In addition, / RANKL+Ave. is the average luminescence intensity of the supernatant after Cell Titer-Glo treatment of cells cultured with each raw material divided by the average luminescence intensity of the supernatant after Cell Titer-Glo treatment of cells cultured in RANKL+ medium (differentiation medium).
[0038] [Table 1]
[0039] [Table 2]
[0040] From the results shown in Table 1 and Figure 1, it can be seen that the materials of the present invention all reduced the fluorescence intensity in the supernatant compared to the control (RANKL+), and have a high bone resorption inhibitory effect. In particular, the fluorescence intensity in the supernatant was significantly reduced in black ginger extract powder, Indian date extract, evening primrose extract, etc., and in particular, the reduction in the fluorescence intensity was confirmed in c-banglein and t-banglein at 1 / 10 the concentration of the other materials. These results demonstrate that each component of the present invention has an excellent bone resorption inhibitory effect, which is comparable to that of bisphosphonates. Furthermore, from the results shown in Table 2 and FIG. 1, it was confirmed that the results in Table 1 and FIG. 1 were not due to cell death caused by the toxicity of the material. These results demonstrate that the present invention provides an excellent bone resorption inhibitory effect that is comparable to that of bisphosphonates.
[0041] Furthermore, in the photograph of Figure 2, the white areas are holes (pits) that have appeared due to calcium absorption. In the RANKL+ of Figure 2, the white areas are large, whereas in the photograph using the material of the present invention, there are very few pits. In other words, as can be seen from the photograph of Figure 2, it can be seen that bone resorption is significantly inhibited according to the present invention.
[0042] (Test Example 2) The material evaluated in Test Example 1 was subjected to a bone density improvement evaluation test. Among these, only representative materials will be disclosed. The models used for evaluation were an LPS-induced bone loss model and a postmenopausal bone loss model. Each of these will be explained below.
[0043] [LPS-induced bone loss model] The materials used are as follows: (animal) Male Slc:ddY mice were delivered at 5 weeks of age, acclimatized for one week, and then used in the experiment at 6 weeks of age (n=4-8).
[0044] (Reagents, etc.) ·LPS (SIGMA: #L2630-100MG) The solution was prepared in saline at 5 mg / 10 mL / kg and stored at 4°C. Saline solution 0.5% CMC Bisphosphonate (Tokyo Chemical Industry Co., Ltd.: #D3921) A solution of 10 mg / 10 ml in 0.5% CMC was used as a positive control.
[0045] (Ingredients used) Java ginger extract (manufactured by Hosoda SHC; standard composition: 5.0% or more as banglen) Evening primrose extract (Oryza Oil & Fat Chemical Co., Ltd.: Evening primrose extract - WSPS) Each raw material was used after being adjusted to 500 mg / 10 ml in 0.5% CMC.
[0046] (procedure) LPS was prepared in physiological saline at 5 mg / 10 mL / kg and administered intraperitoneally to mice on day 0. LPS was administered intraperitoneally in the same manner 4 days later. Each food ingredient was orally administered at 500 mg / 10 mL / kg once daily from day 0 to day 7. Bisphosphonate was orally administered at 10 mg / 10 mL / kg once daily from day 0 to day 7. Four days after the second intraperitoneal administration of LPS, the femurs of the mice were harvested, and the cancellous bone density and trabecular bone density were measured using a μCT (Hitachi Aloka Medical Systems). The results are shown in Table 3 and Figures 3 to 4.
[0047] [Table 3]
[0048] As shown in Table 3 and Figures 3 to 4, the use of evening primrose extract and Java ginger extract reduced the decrease in cancellous bone density and trabecular bone density. These results demonstrated that the use of evening primrose extract or Java ginger extract can improve bone mineral density loss.
[0049] [Postmenopausal bone loss model] The materials used are as follows: (animal) Slc:ddY female mice (age 7 weeks) were delivered and, after one week of acclimation, were used in the experiment at age 8 weeks (n=10).
[0050] (reagent) 0.5% CMC (Ingredients used) Java ginger extract The solution was used after being adjusted to 60 mg / 10 ml in 0.5% CMC.
[0051] (procedure) Under isoflurane anesthesia, the ventral side of the mice was incised, and the left and right ovaries, including the oviducts, were then removed (OVX). In addition, for sham-operated animals, the presence of both ovaries was confirmed under the same conditions, and only suturing was performed without removal. Eight days after ovariectomy or sham operation, the mice were divided into groups, and both groups were orally administered the food ingredient at 60 mg / 10 ml / kg once a day for 12 weeks. After the 12-week administration, femurs were collected and cancellous bone density and trabecular bone density were measured by μCT. The results are shown in Table 4 and FIG.
[0052] [Table 4]
[0053] As shown in Table 4 and FIG. 5, the use of Java ginger extract reduced the loss of cancellous bone density and trabecular bone density. These results demonstrated that the use of Java ginger extract can improve bone mineral density loss even in a postmenopausal bone loss model.
[0054] From the results of Test Examples 1 and 2 above, it was found that the composition for inhibiting bone resorption of the present invention has not only a bone resorption inhibiting effect but also a bone density improving effect.
[0055] (Prescription example) Formulation examples of the bone resorption inhibiting composition of the present invention are given below.
[0056] (Prescription Example 1) [Capsules] composition One selected from c-banglein, t-banglein, L-ascorbyl palmitate, crocetin, evening primrose extract, Indian date extract and black ginger extract (dried product) 100mg Beeswax: 10mg Grape seed oil: 140 mg The above ingredients were mixed and filled into a capsule base containing gelatin and glycerin to prepare seven types of soft capsules.
[0057] (Prescription Example 2) [tablet] composition One selected from c-banglein, t-banglein, L-ascorbyl palmitate, crocetin, evening primrose extract, Indian date extract and black ginger extract (dried product) 150mg Cellulose: 80 mg Starch: 20 mg Sucrose fatty acid esters: 2 mg The above ingredients were mixed and compressed into tablets to prepare seven types of tablets.
[0058] (Prescription Example 3) [Beverage] Composition (mixture; mass%) One selected from c-banglein, t-banglein, L-ascorbyl palmitate, crocetin, evening primrose extract, Indian date extract and black ginger extract (dried product) ··· 1.00 Fructose corn syrup 5.00 Citric acid: 10.4 L-Ascorbic acid 0.20 Fragrance 0.02 Pigment 0.10 Wed...82.28 Seven types of beverages were prepared using the above ingredients in a conventional manner.
Claims
1. A composition for inhibiting bone resorption comprising as an active ingredient one or more components selected from the group consisting of c-banglene, t-banglene, L-ascorbic acid palmitate, crocetin, Java ginger extract, evening primrose extract, Indian date extract and black ginger extract.
2. A composition for improving bone density comprising one or more active ingredients selected from the group consisting of c-banglene, t-banglene, L-ascorbic acid palmitate, crocetin, Java ginger extract, evening primrose extract, Indian date extract and black ginger extract.
